Maternal sirolimus therapy and fetal growth restriction

Fetal growth restriction associated with continued maternal sirolimus therapy in pregnancy has not been reported. We hereby present a case of maternal sirolimus therapy resulting in fetal growth restriction and propose a multi-hit model. This hypothetic model is based on inhibition of mTOR signaling...

Descripción completa

Detalles Bibliográficos
Autores principales: Tshering, Sangay, Dorji, Namkha, Youden, Sonam, Wangchuk, Dorji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: UMF “Gr. T. Popa” Iasi Publishing House 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565690/
https://www.ncbi.nlm.nih.gov/pubmed/34754935
http://dx.doi.org/10.22551/2021.31.0802.10180
_version_ 1784593863115014144
author Tshering, Sangay
Dorji, Namkha
Youden, Sonam
Wangchuk, Dorji
author_facet Tshering, Sangay
Dorji, Namkha
Youden, Sonam
Wangchuk, Dorji
author_sort Tshering, Sangay
collection PubMed
description Fetal growth restriction associated with continued maternal sirolimus therapy in pregnancy has not been reported. We hereby present a case of maternal sirolimus therapy resulting in fetal growth restriction and propose a multi-hit model. This hypothetic model is based on inhibition of mTOR signaling pathway and epigenetic modulation. This case report adds to the paucity of literature on continued monotherapeutic maternal sirolimus in pregnancy and its adverse fetal effects.
format Online
Article
Text
id pubmed-8565690
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher UMF “Gr. T. Popa” Iasi Publishing House
record_format MEDLINE/PubMed
spelling pubmed-85656902021-11-08 Maternal sirolimus therapy and fetal growth restriction Tshering, Sangay Dorji, Namkha Youden, Sonam Wangchuk, Dorji Arch Clin Cases Case Report Fetal growth restriction associated with continued maternal sirolimus therapy in pregnancy has not been reported. We hereby present a case of maternal sirolimus therapy resulting in fetal growth restriction and propose a multi-hit model. This hypothetic model is based on inhibition of mTOR signaling pathway and epigenetic modulation. This case report adds to the paucity of literature on continued monotherapeutic maternal sirolimus in pregnancy and its adverse fetal effects. UMF “Gr. T. Popa” Iasi Publishing House 2021-10-27 /pmc/articles/PMC8565690/ /pubmed/34754935 http://dx.doi.org/10.22551/2021.31.0802.10180 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Tshering, Sangay
Dorji, Namkha
Youden, Sonam
Wangchuk, Dorji
Maternal sirolimus therapy and fetal growth restriction
title Maternal sirolimus therapy and fetal growth restriction
title_full Maternal sirolimus therapy and fetal growth restriction
title_fullStr Maternal sirolimus therapy and fetal growth restriction
title_full_unstemmed Maternal sirolimus therapy and fetal growth restriction
title_short Maternal sirolimus therapy and fetal growth restriction
title_sort maternal sirolimus therapy and fetal growth restriction
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565690/
https://www.ncbi.nlm.nih.gov/pubmed/34754935
http://dx.doi.org/10.22551/2021.31.0802.10180
work_keys_str_mv AT tsheringsangay maternalsirolimustherapyandfetalgrowthrestriction
AT dorjinamkha maternalsirolimustherapyandfetalgrowthrestriction
AT youdensonam maternalsirolimustherapyandfetalgrowthrestriction
AT wangchukdorji maternalsirolimustherapyandfetalgrowthrestriction

Ejemplares similares